Related Experiment Video
Updated: May 30, 2026

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Change of bronchial hyperresponsiveness in asthmatic children
Andjelka Stojković-Andjelković1, Slobodan Obradović, Biljana Vuletić
1'Paediatric Hospital, University Clinical Centre, Kragujevac, Serbia. andja@infosky.net
Insights
Bronchial hyperresponsiveness (BHR) in children with asthma persists despite two years of treatment. Longer anti-inflammatory therapy is needed to fully resolve BHR and improve asthma outcomes.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Respiratory Medicine
Background:
- Bronchial hyperresponsiveness (BHR) is a key predictor of asthma, independent of inflammation.
- Understanding BHR in children is crucial for effective asthma management.
Purpose of the Study:
- To determine the frequency of BHR in asthmatic children.
- To identify predictive factors for BHR.
- To evaluate the impact of GINA and NAEPP prophylaxis on BHR.
Main Methods:
- Evaluated BHR in 106 children using methacholine bronchoprovocation tests.
- Assessed changes in bronchial reactivity and lung function over two years of prophylaxis.
Main Results:
- Symptomatic BHR prevalence was 18%.
- Moderate BHR persisted in most children after two years of prophylaxis.
- While asthma symptoms improved, bronchial sensitivity remained unchanged, influenced by pollution and allergens.
Conclusions:
- Two years of GINA and NAEPP prophylaxis did not fully resolve BHR in asthmatic children.
- Extended anti-inflammatory treatment duration is recommended for moderate BHR in children.
Introduction:
Bronchial hyperresponsiveness (BHR) is a factor in predicting bronchial asthma independently of inflammation markers.
Objective:
The aims were to determine the frequency and important predictive facts of BHR and the effect of prophylaxis by Global Initiative for Asthma (GINA) and National Asthma Education and Prevention Program (NAEPP) on BHR in asthmatic children.
Methods:
BHR in 106 children was evaluated by the bronchoprovocation test with methacholine.
Results:
The prevalence rate of symptomatic BHR is 18% for crucial point of PC20 = 4.1 +/- 3.03 mg/ml and PD20 = 3.22 +/- 2.59 micromol methacholine. On average asthmatic children express moderate BHR, which persists even two years after administering prophylaxis. After two years bronchial reactivity is significantly smaller, the change of FEV1 is significantly smaller, the velocity of change of slope dose response curve (sDRC) is faster and the provocative concentration of methacholine that causes wheezing is 2-3 times lower. A mild sDRC shows milder bronchoconstriction after two years. The fast change of bronchial reactivity in 41% of asthmatic children is contributed to aero-pollution with sulfur dioxide and/or, possible insufficient and/or inadequate treatment during two years of administering prophylaxis. A simultaneous effect of allergens from home environment and grass and tree pollens and of excessive aero-pollution on children's airways is important in the onset of symptomatic BHR. After two years of treatment by GINA and NAEPP children do not show asthma symptoms or show mild asthma symptoms, however bronchial sensitivity remains unchanged.
Conclusion:
Optimal duration of anti-inflammatory treatment in asthmatic children who show moderate bronchial hyperresponsiveness should be longer than two years.
Related Concept Videos
Asthma I: Introduction
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Asthma-I: Introduction
Asthma III: Clinical Manifestations

